Haplo-Identical Bone Marrow Transplantation, “The Glass is Always Half Full”
The young man and his distraught family went from one centre to another. Various forms of chemotherapy and a new drug called Brentuximab were suggested to him by the experts. However, the drug Brentuximab had to be imported and each cycle of treatment would have costed 5 lakhs. Some had suggested an Allogeneic BMT but his only brother was fully mismatched with him and this option was no longer a consideration.
Dr Suparno Chakrabarti and Dr Sarita Jaiswal had been running a HAPLOIDENTICAL BMT PROGRAM in the country for 3 years and the patient and his father came to them at Dharamshila BMT Centre despite all the other experts in the country discouraging them to go for such an option. At the outset, the patient was given standard chemotherapy which showed an initial response, but as it had happened so many times before, the cancer bounced back. The patients parents were half matched with him as expected, but the team at Dharamshila realised that just doing the BMT is not going to help the young man. They identified a unique population of white blood cells in the father, but not in the mother which could kill the tumour cells without causing any adverse reaction in the patient. They are called ‘KIR ligand mismatched NK cells’’. These cells were analysed and were found very effective in killing tumour cells in the test tube. Dr Sarita Jaiswal had been trained in transplants involving such cell manipulations at Italy and USA. The patient’s body could not have received any further intensive chemotherapy. They sought help from Dr Kanika Sharma to administer a small dose of radiation to the entire body keeping in mind that he has already received a very large dose of radiation to his heart, lungs and neck. With this tiny dose of radiation and some immunosuppressive drugs the patient was infused half matched cells from his father and 7 days later his father’s white cells were collected and the special cells were separated and infused to the patient.
The stem cells from the father started growing in the patient after 2 weeks and he remained free of all bacterial and viral infections since then. The blood and bone marrow of the patient were regularly analysed and it showed that the cells from the father which were supposed to be killing the tumour without causing any reaction in the patient, were growing in number.
Five months after the BMT, a PET scan was done to see the state of the cancer. To everyone’s joy and surprise, it had disappeared completely.
Few such cases have been reported worldwide and this is the first time Indian doctors have used innovation, science and technology to cure such a refractory cancer. Dr Sarita Jaiswal had seen some very impressive results with Haploidentical BMT using cell manipulation, but to replicate the procedure in its entirety would cost 40 lakhs at least. Hence, Dr Sarita innovated this unique way of carrying out the Half matched BMT at a low cost and administer selective cells at the right time which shall help in hitting the tumour as well as fighting infections.
Several such Haploidentical BMT using this unique and innovative technology are being carried out by Dr Sarita Jaiswal at Dharamshila BMT Centre. Dr Sarita says that it is not just about giving the cells but understanding the science behind it and applying it in the right context in the correct way. Dr Suversha Khanna, who had long dreamt of a BMT unit at Dharamshila Hospital expressed her satisfaction at the optimum utilisation of the world class infrastructure so painstakingly erected in the hospital, 20 years after its inception. She said that that there is little point in having yet another BMT centre, if it’s not going to make a difference to the majority of the suffering patients. Today, with the infrastructure and the expertise of the BMT team, ably supported by Radiation Oncologists, its possible that every patient who needs a BMT can have one from a Half matched (HAPLOIDENTICAL) Parents, Siblings or Children and with the right choice of donor can even get cured of otherwise refractory blood or lymph gland cancers. Dr Suparno Chakrabarti who had started such transplants for the first time in India says that the ‘glass is always half full’.
Passion for Excellence in Cancer Care
A group of concerned relatives and friends of cancer patients felt the need to provide complete cancer treatment under one roof. They felt it was their “Dharma” (duty) to provide to cancer patients what was not available to their near and dear ones, when they were suffering from cancer. They laid the “Shila” (foundation) of their duty by registering a NGO, Dharamshila Cancer Foundation And Research Centre (DCFRC) on 19 April, 1990.
DCFRC Commissioned the first phase of the Dharamshila Cancer Hospital And Research Centre (DCHRC) with 100 beds in 1994 and expanded to 300 beds in 2006, with the sole objective of making cancer treatment available, accessible and affordable.
Being totally focused on cancer for more than two decades, Dharamshila is continuously adding world class cutting edge technologies for early diagnosis and cancer treatment.
Dharamshila Hospital is the most trusted cancer hospital for patients from all over India and neighbouring countries for its policy of avoiding unnecessary procedures/hospitalization and transparent billing. Dharamshila hospital has won the goodwill of thousands of Patients who are enjoying cancer free life.
Highly qualified skilled and experienced teams of organ specific cancer specialists practice evidence based medicine and follow international treatment guidelines to achieve best treatment outcomes.
Being sensitive to the physical, medical, emotional and financial needs of patients, Dharamshila strives to serve patients with love, devotion, compassion, commitment and positive attitude.
High quality standards of treatment, complete patient safety and satisfaction, improving cure rates and adding quality to life will always remain our hallmark.
Dharamshila Hospital and Research Centre
Near New Ashok Nagar Metro Station,
Vasundhara Enclave, Delhi - 110096, INDIA
Tel: 011 - 43066353 (9:00 AM to 6:00 PM) ,
Fax: 011 - 22617770 / 22619033 / 22618574
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Haplo-Identical Bone Marrow Transplantation, “The Glass is Always Half Full” here
News-ID: 297199 • Views: 8905
More Releases from Dharamshila Hospital and Research Centre
Most Promising Healthcare Chain 2014 for Dharamshila Hospital & Research Centre
Eminent Healthcare Expert Dr Sandeep Chatrath receives the prestigious India’s Most Promising Healthcare Chain 2014 for Dharamshila Hospital & Research Centre ILc Power Brand 2014. Dr Sandeep Chatrath also declared by the Jury as the CEO of the Year Healthcare 2014 at Asia’s Biggest Leadership Event, the 5th Annual India Leadership Conclave 2014 The prestigious & coveted Awards were presented in a glittering award ceremony
Dharamshila Hospital Urges To Join Hands To Fight Against Cancer In Children
New Delhi, June 21, 2012: Childhood cancer contributes to nearly 5% of the total cancer burden in India, with approximately 45,000 children diagnosed with cancer every year. As increasing prevalence of cancer among children is becoming a cause of great concern, there is an urgent need to spread awareness about childhood cancers, for timely detection and treatment, say doctors at Dharamshila Hospital and Research Centre, India’s first and only NABH
Dharamshila Hospital Organized A Live Workshop on Composite Resection with Micro …
New Delhi, May 5, 2012 : A live workshop on Head and Neck Cancer Surgeries was organized at Dharamshila Hospital And Research Centre (DHRC). Worldwide Head and Neck cancers are sixth most common cancers in men. In India Head and Neck Cancers are 2nd most common among men and are responsible for 40% of new cancer cases detected annually. Even though 75% of Head and Neck Cancers are caused by
Dharamshila Hospital start its Cancer OPD in Patna, Bihar at Ford Hospital to ca …
New Delhi, Feburary 1, 2012 Dharamshila Hospital And Research Centre, India’s first and only NABH accredited Cancer Hospital, going to start its Cancer OPD in Bihar at Ford Hospital And Research Centre, Patna on 4th and 5th Feburary 2012. Bihar has recorded an alarming rise in the incidence of cancer with an estimated 200,000 people suffering from this killer disease. Lack of awareness among the people about the disease coupled
More Releases for BMT
Marine Big Data Market 2018 Leading companies – Teradata, Oceanwise, Splunk, B …
Qyresearchreports include new market research report “Global Marine Big Data Market Size, Status and Forecast 2025” to its huge collection of research reports. The global Marine Big Data market is evolving at an exciting pace driven by changing dynamics and risk ecosystem, an analysis of which forms the crux of the report. The study on the global Marine Big Data market takes a closer look at several regional trends and the
Global Weather Forecasting Services Market 2018 Key Players: Stormgeo, BMT Group …
Weather Forecasting Services Market: WiseGuyReports.com adds “Weather Forecasting Services Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting 2025” reports tits database. Executive Summary Weather forecasting is the application of science and technology to predict the conditions of the atmosphere for a given location and time. Human beings have attempted to predict the weather informally for millennia and formally since the 19th century. The weather forecasting services market has been studied in
Alpha Mannosidosis Market: BMT Emerges as Leading Therapy for Treating Alpha Man …
Cytomedix Inc. and Zymenex A/S are leading the global market for alpha mannosidosis, finds a new research report by Transparency Market Research (TMR). The competitive landscape in this market is a bit concentrated and both the leading players are actively working on conducting clinical trials for the development of various molecule types and monotherapy and combination products. They are also emphasizing on designing advance route of administration. Over the coming
Jan 12, 2018: Can Seamers Market Size 2023 JK Somme, Stiller GmbH, Dixie, BMT
Can Seamers Market Research 2018 Recently published a detailed market study on the "Can Seamers Market" across the global, regional and country level. The report on the global Can Seamers market uses the top-down and bottom-up approaches to define, analyze, and describe the Can Seamers market 2018 trends for the next five years up to 2023. The Can Seamers market report further provides production, capacity, Can Seamers market price per
Surgical Instruments Market Share 2017-2022 SIM Surgical, BMT Medizintechnik Gmb …
Global Surgical Instruments Market Research Report Recently published a detailed market study on the "Surgical Instruments Market" across the global, regional and country level. The report on the global Surgical Instruments market uses the top-down and bottom-up approaches to define, analyze, and describe the market trends for the next five years. The Surgical Instruments market report further provides production, capacity, Surgical Instruments market price per region, gross margin, production cost, for
Floating Seahorse Market 2017- Kleindienst Group, BMT Group, HEART OF EUROPE
Apex Research, recently published a detailed market research study focused on the "Floating Seahorse Market" across the global, regional and country level. The report provides 360° analysis of "Floating Seahorse Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Floating Seahorse industry, and estimates the future trend of Floating Seahorse market on